A 58-page, 14-observation FDA Form 483 issued after a recent US FDA inspection of Zimmer Biomet Holdings Inc. ’s Warsaw, Ind., plant is likely to lead to a warning letter and ongoing remediation efforts, one analysis states.
The firm issued a statement Dec. 14 acknowledging receiving the FDA-483 form. Analysts at Wells Fargo Securities obtained the form...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?